Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clara Montagut

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
The Oncologist|March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Nature Communications|May 23, 2022
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosisLaura Solé, Teresa Lobo-Jarne, Daniel Álvarez-Villanueva, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Gut|July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium studyRavit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2018
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal CancerIván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, et al.
JCO Precision Oncology|February 1, 2022
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor TherapyJoan Maurel, Vicente Alonso, Pilar Escudero, et al.
Nature Communications|February 10, 2023
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapyJenniffer Linares, Anna Sallent-Aragay, Jordi Badia-Ramentol, et al.
Nature Medicine|June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsGiulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
Nature Immunology|March 22, 2025
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppressionAnna Rea, Sara Santana-Hernández, Javier Villanueva, et al.
JAMA Oncology|February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical TrialClara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
The Oncologist|March 13, 2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)Johanna C Bendell, Tamara Sauri, Antonio Cubillo Gracián, et al.
Nature Communications|May 23, 2022
p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosisLaura Solé, Teresa Lobo-Jarne, Daniel Álvarez-Villanueva, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingUltan McDermott, Sreenath V Sharma, Lori Dowell, et al.
Gut|July 12, 2014
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium studyRavit Geva, Loredana Vecchione, Konstantinos T Kalogeras, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2018
Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal CancerIván Prieto-Potin, Clara Montagut, Beatriz Bellosillo, et al.
JCO Precision Oncology|February 1, 2022
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor TherapyJoan Maurel, Vicente Alonso, Pilar Escudero, et al.
Nature Communications|February 10, 2023
Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapyJenniffer Linares, Anna Sallent-Aragay, Jordi Badia-Ramentol, et al.
Nature Medicine|June 2, 2015
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsGiulia Siravegna, Benedetta Mussolin, Michela Buscarino, et al.
Nature Immunology|March 22, 2025
Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppressionAnna Rea, Sara Santana-Hernández, Javier Villanueva, et al.
JAMA Oncology|February 10, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical TrialClara Montagut, Guillem Argilés, Fortunato Ciardiello, et al.
Pageof 8